Get the Stockscreener App
23.16
2.06%
-0.47
Viridian Therapeutics Inc stock is traded at $23.16, with a volume of 828.06K.
It is down -2.06% in the last 24 hours and up +6.90% over the past month.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
See More
Previous Close:
$23.63
Open:
$23.5
24h Volume:
828.06K
Relative Volume:
0.83
Market Cap:
$1.89B
Revenue:
$305.00K
Net Income/Loss:
$-328.98M
P/E Ratio:
-5.43
EPS:
-4.2652
Net Cash Flow:
$-309.60M
1W Performance:
+2.68%
1M Performance:
+6.90%
6M Performance:
+69.92%
1Y Performance:
+3.88%
1-Day Range:
$22.70
$23.94
1-Week Range:
$22.35
$24.23
52-Week Range:
$9.90
$27.20
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Name
Viridian Therapeutics Inc
Sector
Industry
Phone
617.272.4600
Address
221 CRESCENT STREET, WALTHAM
Compare VRDN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
23.16 | 2.20B | 305.00K | -328.98M | -309.60M | -4.2652 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.27 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
639.86 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.38 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
824.41 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.15 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-25-25 | Resumed | Jefferies | Buy |
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-25-24 | Initiated | TD Cowen | Buy |
| Sep-11-24 | Reiterated | Needham | Buy |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Jun-06-24 | Initiated | Goldman | Buy |
| May-09-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| May-09-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-14-23 | Initiated | BTIG Research | Buy |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| May-30-23 | Initiated | RBC Capital Mkts | Outperform |
| Apr-17-23 | Initiated | Wells Fargo | Overweight |
| Mar-30-23 | Initiated | Stifel | Buy |
| Dec-19-22 | Initiated | Cowen | Outperform |
| Dec-19-22 | Initiated | Needham | Buy |
| Dec-16-22 | Initiated | Credit Suisse | Outperform |
| Dec-01-22 | Initiated | H.C. Wainwright | Buy |
| Jun-23-22 | Initiated | B. Riley Securities | Buy |
| Nov-18-21 | Initiated | SVB Leerink | Outperform |
| Oct-12-21 | Initiated | Evercore ISI | Outperform |
| Jan-25-21 | Initiated | Ladenburg Thalmann | Buy |
View All
Viridian Therapeutics Inc Stock (VRDN) Latest News
Smart tools for monitoring Viridian Therapeutics Inc.’s price action2025 Geopolitical Influence & Real-Time Chart Pattern Alerts - newser.com
Viridian Therapeutics submits Biologics License Application to FDA for veligrotug - Ophthalmology Times
Viridian Therapeutics submits BLA for thyroid disease drug - Traders Union
Viridian Therapeutics (VRDN) Submits BLA for Veligrotug to FDA - GuruFocus
Trend analysis for Viridian Therapeutics Inc. this weekWeekly Risk Report & AI Forecast for Swing Trade Picks - newser.com
Can Viridian Therapeutics Inc. stock attract ESG capital inflowsJuly 2025 Pullbacks & Daily Stock Momentum Reports - newser.com
Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease - The Joplin Globe
How hedge fund analytics apply to Viridian Therapeutics Inc. stockTrade Ideas & Weekly High Momentum Picks - newser.com
Can swing trading help recover from Viridian Therapeutics Inc. lossesShare Buyback & Community Consensus Trade Alerts - newser.com
Will Viridian Therapeutics Inc. (1S1) stock attract long term capital inflows2025 Key Lessons & Fast Exit and Entry Trade Guides - newser.com
How buybacks impact Viridian Therapeutics Inc. stock valueWeekly Trade Review & Long-Term Capital Growth Ideas - newser.com
Top chart patterns to watch in Viridian Therapeutics Inc.Bull Run & Weekly High Momentum Picks - newser.com
Why Viridian Therapeutics Inc. (1S1) stock is a must watch tickerWeekly Stock Analysis & Verified Chart Pattern Signals - newser.com
Regression analysis insights on Viridian Therapeutics Inc. performanceDay Trade & Free Verified High Yield Trade Plans - newser.com
Is Viridian Therapeutics Inc. stock attractive for growth ETFsSell Signal & Community Consensus Trade Alerts - newser.com
Chart based analysis of Viridian Therapeutics Inc. trendsJuly 2025 Retail & AI Forecasted Entry and Exit Points - newser.com
Oppenheimer Maintains Viridian Therapeutics (VRDN) Outperform Recommendation - MSN
How Viridian Therapeutics Inc. stock reacts to job market dataEarnings Growth Summary & Free Community Supported Trade Ideas - newser.com
Moody Aldrich Partners LLC Has $1.25 Million Stake in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Reassessing Viridian Therapeutics (VRDN) Valuation Following Insider Buying and Progress in Thyroid Eye Disease Program - Sahm
Astria, Viridian Therapeutics, and More Stocks See Action From Activist Investors - Barron's
Fairmount Funds Management LLC's Strategic Acquisition in Viridi - GuruFocus
Wedbush Reduces Earnings Estimates for Viridian Therapeutics - MarketBeat
Can machine learning forecast Viridian Therapeutics Inc. recoveryGold Moves & Fast Entry Momentum Trade Alerts - newser.com
How supply chain issues affect Viridian Therapeutics Inc. stock2025 Top Decliners & Free High Return Stock Watch Alerts - newser.com
How Viridian Therapeutics Inc. stock performs in interest rate cyclesEarnings Miss & Consistent Growth Stock Picks - newser.com
Is Viridian Therapeutics Inc. (1S1) stock a buy on weaknessTrade Volume Report & Real-Time Volume Surge Alerts - newser.com
Using Ichimoku Cloud for Viridian Therapeutics Inc. technicalsEarnings Overview Report & Short-Term High Return Ideas - newser.com
Wedbush Expects Reduced Earnings for Viridian Therapeutics - MarketBeat
Can Viridian Therapeutics Inc. (1S1) stock survive global slowdownWeekly Trend Report & Fast Moving Market Watchlists - newser.com
Viridian Therapeutics Inc Stock (VRDN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
0.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):